Patents by Inventor Rejean Fortin

Rejean Fortin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
    Patent number: 6046217
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: April 4, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Friesen, Rejean Fortin, Daniel Dube, Denis Deschenes
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Patent number: 6001843
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: December 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • Method for measuring metaplastic changes of mucus secreting epithelial cells
    Patent number: 5932481
    Abstract: A method for the rapid estimation of hyperplastic and hypertrophic changes in animal airways is an assay which specifically measures acidic and neutral mucoproteins in a linear fashion from 0.5 to at least 10 .mu.g. The assay comprises exposure of a test animal to a suspected metaplastic inducer, removal of the lungs, homogenization in an appropriately buffered solution containing reducing agents and protease inhibitors; removal of particulate matter; and size-fractionation of the SDS treated soluble extract. The high molecular weight material is immobilized and stained for either acidic or neutral mucosubstances and the specific staining is quantitated. The changes observed are consistent with those seen in histological sections of the exposed tissues.
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: August 3, 1999
    Assignee: Merck Frosst Canada & Co.
    Inventors: Douglas J. Pon, Louise Boulet, Carlo J. van Staden, Rejean Fortin
  • Substituted pyridines as selective cyclooxygenase-2 inhibitors
    Patent number: 5861419
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: January 19, 1999
    Assignee: Merck Frosst Canad, Inc.
    Inventors: Daniel Dube, Richard Friesen, Rejean Fortin, Zhaoyin Wang, Jacques Yves Gauthier
  • Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
    Patent number: 5817700
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: October 6, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Dube, Rejean Fortin, Richard Frenette, Richard Friesen, Daniel Guay, Sylvie Prescott
  • Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis
    Patent number: 5428060
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: June 27, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, John W. Gillard, Rejean Fortin, Daniel Dube, Yves Girard, Pierre Hamel, Daniel Delorme
  • Heteroaryl coumarins as inhibitors of leukotriene biosynthesis
    Patent number: 5424320
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: June 13, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Rejean Fortin, Yves Girard, Erich Grimm, John Hutchinson, John Scheigetz
  • (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5380850
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: January 10, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Petpiboon Prasit, Rejean Fortin, John H. Hutchinson, Michel L. Belley, Serge Leger, Richard Frenette, John Gillard
  • Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis
    Patent number: 5360815
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: November 1, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Rejean Fortin, Yves Girard, Erich Grimm, John Hutchinson, John Scheigetz
  • Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
    Patent number: 5308852
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: May 3, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Girard, Daniel Delorme, Rejean Fortin, Daniel Dube, Pierre Hamel, Carol Lepine, Yves Ducharme
  • (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5272145
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: December 14, 1992
    Date of Patent: December 21, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Petpiboon Prasit, Rejean Fortin, John H. Hutchinson, Michel L. Belley, Serge Leger, Richard Frenette, John Gillard
  • Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis
    Patent number: 5252599
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: October 12, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Girard, Rejean Fortin, Daniel Delorme, Daniel Dube, Pierre Hamel, Yves Ducharme, John W. Gillard
  • 3-hetero-substituted-N-benzyl-indoles and medical methods of use therefor
    Patent number: 5225421
    Abstract: Compounds having the formula: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti asthmatic, anti allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: September 16, 1991
    Date of Patent: July 6, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John W. Gillard, Howard E. Morton, Rejean Fortin, Yvan Guindon
  • (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5204344
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: February 5, 1991
    Date of Patent: April 20, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Petpiboon Prasit, Rejean Fortin, John H. Hutchinson, Michel L. Belley, Serge Leger, John Gillard, Richard Frenette
  • Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis
    Patent number: 5202321
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, psoriasis, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: June 13, 1991
    Date of Patent: April 13, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John H. Hutchinson, Yves Girard, Rejean Fortin, Dwight MacDonald, John Scheigetz, Daniel Delorme, Michel Therien, Pierre Hamel
  • 5-lipoxygenase activating protein
    Patent number: 5182367
    Abstract: An 18kD protein (FLAP) has been isolated from rat and human cells which is necessary for production of leukotrienes from arachidonic acid in mammalian cells containing 5-lipoxygenase. The gene (cDNA) encoding for FLAP has also been produced.
    Type: Grant
    Filed: November 30, 1990
    Date of Patent: January 26, 1993
    Assignees: Merck & Co., Inc., Merck Frosst Canada, Inc.
    Inventors: John W. Gillard, Jacques-Yves Gauthier, Jillian F. Evans, Rejean Fortin, Yvan Guinon, Richard A. F. Dixon, Douglas K. Miller
  • Leukotriene antagonists
    Patent number: 5135940
    Abstract: Compounds of the Formulae: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4 and E.sub.4, the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.
    Type: Grant
    Filed: March 20, 1991
    Date of Patent: August 4, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Patrice C. Belanger, Joshua Rokach, Rejean Fortin, Christiane Yoakim, Yvan Guindon
  • 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis
    Patent number: 5132319
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: March 28, 1991
    Date of Patent: July 21, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Girard, Pierre Hamel, Daniel Delorme, Rejean Fortin
  • 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
    Patent number: 5081138
    Abstract: Compounds having the formula: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: December 9, 1987
    Date of Patent: January 14, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John W. Gillard, Howard E. Morton, Rejean Fortin, Yvan Guindon
  • Indole-2-alkanoic acids compositions of and anti allergic use thereof
    Patent number: 5081145
    Abstract: Indole-2-alkanoic acids are disclosed. The compounds act as prostaglandin and thromboxane antagonists and are useful in treating asthma, inflammation, diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion and dismenorrhea and as cytoprotective agents.
    Type: Grant
    Filed: February 1, 1990
    Date of Patent: January 14, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yvan Guindon, John W. Gillard, Christiane Yoakim, Thomas R. Jones, Rejean Fortin